Treatment of Parkinson's disease
Identifieur interne : 002E96 ( Main/Exploration ); précédent : 002E95; suivant : 002E97Treatment of Parkinson's disease
Auteurs : W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada]Source :
- Canadian journal of neurological sciences [ 0317-1671 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Agonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Catechol O-methyltransferase, Chemotherapy, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dopamine receptor, Dyskinesias (etiology), Enzyme inhibitor, Holistic Health, Human, Humans, Levodopa, Levodopa (adverse effects), Musculoskeletal Manipulations, Neuroprotective Agents (therapeutic use), Occupational Therapy, Parkinson Disease (nursing), Parkinson Disease (rehabilitation), Parkinson Disease (therapy), Parkinson disease, Reeducation, Speech Therapy, Treatment.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Neuroprotective Agents.
- etiology : Dyskinesias.
- nursing : Parkinson Disease.
- rehabilitation : Parkinson Disease.
- therapy : Parkinson Disease.
- Holistic Health, Humans, Musculoskeletal Manipulations, Occupational Therapy, Speech Therapy.
Abstract
Le traitement de la maladie de Parkinson. La maladie de Parkinson est une maladie neurodégénératrice progressive dont le traitement nécessite une approche holistique. Les interventions tant pharmacologiques que non pharmacologiques jouent un rôle important dans la prise en charge de cette maladie. Bien que la lévodopa demeure la pierre angulaire du traitement symptomatique, les agonistes de la dopamine jouent un rôle de plus en plus important. Les complications motrices de la thérapie dopaminergique constituent un problème important, particulièrement chez les patients en phase avancée de la maladie qui prennent de la lévodopa depuis plusieurs années. Les interventions thérapeutiques doivent être adaptées à chaque patient et modifiées à mesure que la maladie progresse, dans le but de minimiser autant que possible l'invalidité fonctionnelle.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000A74
- to stream PascalFrancis, to step Curation: 000249
- to stream PascalFrancis, to step Checkpoint: 000908
- to stream Main, to step Merge: 003294
- to stream PubMed, to step Corpus: 001446
- to stream PubMed, to step Curation: 001446
- to stream PubMed, to step Checkpoint: 001446
- to stream Ncbi, to step Merge: 000294
- to stream Ncbi, to step Curation: 000294
- to stream Ncbi, to step Checkpoint: 000294
- to stream Main, to step Merge: 003128
- to stream Main, to step Curation: 002E96
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of Parkinson's disease</title>
<author><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W. R. Wayne" last="Martin">W. R. Wayne Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, University of Alberta</s1>
<s2>Edmonton, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Edmonton, AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, University of Alberta</s1>
<s2>Edmonton, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Edmonton, AB</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0282004</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0282004 INIST</idno>
<idno type="RBID">Pascal:03-0282004</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A74</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000249</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000908</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000908</idno>
<idno type="wicri:doubleKey">0317-1671:2003:Martin W:treatment:of:parkinson</idno>
<idno type="wicri:Area/Main/Merge">003294</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12691474</idno>
<idno type="wicri:Area/PubMed/Corpus">001446</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001446</idno>
<idno type="wicri:Area/PubMed/Curation">001446</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001446</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001446</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001446</idno>
<idno type="wicri:Area/Ncbi/Merge">000294</idno>
<idno type="wicri:Area/Ncbi/Curation">000294</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000294</idno>
<idno type="wicri:doubleKey">0317-1671:2003:Martin W:treatment:of:parkinson</idno>
<idno type="wicri:Area/Main/Merge">003128</idno>
<idno type="wicri:Area/Main/Curation">002E96</idno>
<idno type="wicri:Area/Main/Exploration">002E96</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of Parkinson's disease</title>
<author><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W. R. Wayne" last="Martin">W. R. Wayne Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, University of Alberta</s1>
<s2>Edmonton, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Edmonton, AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, University of Alberta</s1>
<s2>Edmonton, AB</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Edmonton, AB</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine receptor</term>
<term>Dyskinesias (etiology)</term>
<term>Enzyme inhibitor</term>
<term>Holistic Health</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Musculoskeletal Manipulations</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Occupational Therapy</term>
<term>Parkinson Disease (nursing)</term>
<term>Parkinson Disease (rehabilitation)</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinson disease</term>
<term>Reeducation</term>
<term>Speech Therapy</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="nursing" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="rehabilitation" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Holistic Health</term>
<term>Humans</term>
<term>Musculoskeletal Manipulations</term>
<term>Occupational Therapy</term>
<term>Speech Therapy</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Inhibiteur enzyme</term>
<term>Catechol O-methyltransferase</term>
<term>Rééducation</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="fr">Le traitement de la maladie de Parkinson. La maladie de Parkinson est une maladie neurodégénératrice progressive dont le traitement nécessite une approche holistique. Les interventions tant pharmacologiques que non pharmacologiques jouent un rôle important dans la prise en charge de cette maladie. Bien que la lévodopa demeure la pierre angulaire du traitement symptomatique, les agonistes de la dopamine jouent un rôle de plus en plus important. Les complications motrices de la thérapie dopaminergique constituent un problème important, particulièrement chez les patients en phase avancée de la maladie qui prennent de la lévodopa depuis plusieurs années. Les interventions thérapeutiques doivent être adaptées à chaque patient et modifiées à mesure que la maladie progresse, dans le but de minimiser autant que possible l'invalidité fonctionnelle.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W. R. Wayne" last="Martin">W. R. Wayne Martin</name>
</noRegion>
<name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:03-0282004 |texte= Treatment of Parkinson's disease }}
This area was generated with Dilib version V0.6.29. |